Shares of TG Therapeutics Inc. (NASDAQ:TGTX) were down 3.3% during trading on Friday . The stock traded as low as $6.05 and last traded at $6.10, with a volume of 159,867 shares changing hands. The stock had previously closed at $6.31.

Several analysts have recently commented on TGTX shares. Brean Capital reiterated a “buy” rating on shares of TG Therapeutics in a research report on Monday, June 13th. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a research report on Monday, June 13th. Roth Capital reiterated a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a research report on Thursday, June 9th. SunTrust Banks Inc. started coverage on shares of TG Therapeutics in a research report on Friday, May 27th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Zacks Investment Research lowered shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 14th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $22.33.

The stock’s 50-day moving average is $6.33 and its 200 day moving average is $8.04. The stock’s market cap is $319.60 million.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.08. On average, analysts forecast that TG Therapeutics Inc. will post ($1.15) EPS for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund boosted its position in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned about 0.43% of TG Therapeutics worth $2,671,000 at the end of the most recent reporting period.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.